Palisade Bio, Inc. (NASDAQ:PALI) reported a wider-than-expected loss for the third quarter on Tuesday.

The company posted quarterly losses of 7 cents per share which missed the analyst consensus estimate of losses of 6 cents per share.

“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress,” said JD Finley, Chief Executive Officer of Palisade Bio. “In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”

Palisade Bio shares gained 3.1% to trade at $1.1650 on Wednesday.

These analysts made changes to their price targets on Palisade Bio following earnings announcement.

• HC Wainwright & Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and lowered the price target from $7 to $5.
• Piper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and cut the price target from $25 to $16.

Considering buying PALI stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.